

# Conference Agenda

## Tuesday, July 15

7:00 a.m. Conference Registration / Continental Breakfast

7:30 a.m. Introduction

7:45 a.m. Welcome Address  
Vijaya Raj Bhatt, MBBS, MS; Nitin Jain, MD; Marina Konopleva, MD, PhD; and Matthew Lunning, DO, FACP

### Acute Myeloid Leukemia (AML)

Moderators: Vijaya Raj Bhatt, MBBS, MS and Heidi D. Klepin, MD, MS

8:00 a.m. World Health Organization (WHO) Classification in AML and Myelodysplastic Syndrome (MDS)  
Joseph D. Khoury, MD

8:15 a.m. Harmonizing WHO and International Consensus Classification (ICC) Classification in AML and MDS  
Sanam Loghavi, MD

8:30 a.m. Measurable Residual Disease (MRD) in AML: What Are the Implications?  
Jerald P. Radich, MD

8:45 a.m. Geriatric Assessment in Leukemia: Why Should You Care?  
Vijaya Raj Bhatt, MBBS, MS

9:00 a.m. Questions and Answers

### Choosing Wisely: Upfront Treatment Intensity Selection in Adults with AML

#### Intensive Chemotherapy in Adults

9:15 a.m. Yes, and I Go Beyond 7+3  
Richard M. Stone, MD

9:30 a.m. No, I Use Lower Intensity Chemotherapy  
Keith W. Pratz, MD

#### Intensive Chemotherapy in Younger Adults

9:45 a.m. Yes, I Integrate Novel Therapies with Intensive Chemotherapy  
Tapan M. Kadia, MD

10:00 a.m. No, It is Prime Time for Upfront Lower Intensity Triplet Therapies  
Eunice S. Wang, MD

10:15 a.m. Questions and Answers

10:30 a.m. Break

### Debate/Discussion: Treatment Options for Relapsed or Refractory (R/R) AML

Moderators: Joann B. Sweasy, PhD and Geoffrey L. Uy, MD

10:50 a.m. Targeted Therapies in R/R AML  
Naval G. Daver, MD

11:05 a.m. Targeted Radiotherapies and Other Novel Therapies in R/R AML  
Geoffrey L. Uy, MD

11:20 a.m. Immediate Allogeneic Transplant  
Krishna Gundabolu, MBBS, MS

11:35 a.m. Questions and Answers

11:50 a.m. Lunch Break (On Your Own)

### Interprofessional Education

Moderators: Katherine L. Byar, MSN, ANP, BC, BMTCN® and Kim Schmit-Pokorny, MSN, RN, OCN®, BMTCN®

1:00 p.m. Managing Platelet Refractoriness During Intensive Antileukemia Chemotherapy  
Aleh (Oleg) Bobr, MD

1:15 p.m. Safely Using New and Targeted Therapies for Acute Myeloid Leukemia  
Allison M. Graner, PharmD, BCOP and Caitlin R. Rausch, PharmD, BCOP

1:45 p.m. Mitigating Risks of Intensive Acute Lymphoblastic Leukemia (ALL) Therapies and Monoclonal Antibodies  
Jared E. Matya, PharmD, BCOP and Shilpa Paul, PharmD, BCOP

2:15 p.m. Supportive Care in Older Adults with Hematological Malignancies  
Kah Poh Loh, BMedSci, MBBCh, BAO, MS

2:30 p.m. Team Science Approach to Managing Patients with Leukemia  
Katherine L. Byar, MSN, ANP, BC, BMTCN®

2:45 p.m. Supporting Adolescent/Young Adult (AYA) Patients Undergoing Leukemia Treatment and Transitioning Care from Pediatric to Adult Teams  
Kimberly Miller, BSN, RN, BMTCN® and Rachael L. Schmidt, DNP, FNP-C, AOCNP®

3:00 p.m. Questions and Answers

3:15 p.m. Adjourn

### Welcome Reception

7:00-9:00 p.m.

Conference participants and registered accompanying guests are invited to join. Name badges required.





## Wednesday, July 16

7:00 a.m. Continental Breakfast

### Acute Lymphoblastic Leukemia (ALL)

Moderators: Ryan D. Cassaday, MD and Nitin Jain, MD

7:45 a.m. **Keynote Address**  
Progress in Adult ALL: Last 10 Years and the Future Ahead  
Hagop M. Kantarjian, MD

8:15 a.m. What Have We Learned from Genetics of B-ALL and T-ALL?  
Charles G. Mullighan, MBBS (Hons), MSc, MD

8:30 a.m. Questions and Answers

### How Do I...

8:45 a.m. How Do I Treat Adults with Newly Diagnosed Ph-Negative B-ALL?  
Marlise R. Luskin, MD, MSCE

9:00 a.m. How Do I Treat Central Nervous System Disease in ALL?  
Ryan D. Cassaday, MD

9:15 a.m. How Do I Use CAR-T in Adult ALL?  
Lori Muffly, MD, MS

9:30 a.m. How Do I Use CAR-T in Pediatric ALL?  
Stephan A. Grupp, MD, PhD

9:45 a.m. Questions and Answers

10:00 a.m. Break

### Chemotherapy Options for Upfront Management of ALL

10:20 a.m. Use of Asparaginase in ALL – When and How  
Wendy Stock, MD

10:35 a.m. Chemotherapy-Free Regimens for Ph-Positive ALL  
Elias Jabbour, MD

10:50 a.m. BCL2 and BCL-XL Inhibition in ALL – Ready for Primetime?  
Marina Konopleva, MD, PhD

11:05 a.m. Questions and Answers

### Myeloproliferative Neoplasms (MPN)

Moderators: Laura C. Michaelis, MD and Naveen Pemmaraju, MD

11:20 a.m. How Many Janus Kinase (JAK) Inhibitors Do We Need in Myelofibrosis (MF)?  
Ruben Mesa, MD, FACP

11:35 a.m. Can We Modify the Disease in MF? How?  
Naveen Pemmaraju, MD

11:50 a.m. What's New in Polycythemia Vera?  
Olatoyosi Odenike, MD

12:05 p.m. What's New in Essential Thrombocythaemia?  
Laura C. Michaelis, MD

12:20 p.m. Questions and Answers

12:35 p.m. Lunch Break (On Your Own)

### Meet the Experts

3:00 p.m. Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS)  
Moderator: Vijaya Raj Bhatt, MBBS, MS  
Experts: Geoffrey L. Uy, MD; Eunice S. Wang, MD; and Olatoyosi Odenike, MD

4:00 p.m. Chronic Lymphocytic Leukemia (CLL)  
Moderator: Nitin Jain, MD  
Experts: Julie M. Vose, MD, MBA; Susan M. O'Brien, MD; and Matthew A. Lunning, DO, FACP

5:00 p.m. Adjourn

## Thursday, July 17

7:00 a.m. Continental Breakfast

### Myelodysplastic Syndrome (MDS) and Clonal Hematopoiesis

Moderators: Olatoyosi Odenike, MD and Mikkael A. Sekeres, MD, MS

7:45 a.m. Molecular International Prognostic Scoring System (IPSS-M): How Does It Affect Treatment Selection?  
Elli Papaemmanuil, PhD

8:00 a.m. Biology of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Clonal Cytopenia of Undetermined Significance (CCUS)  
Mrinal S. Patnaik, MBBS

8:15 a.m. Improving the Health of Patients with CHIP/CCUS  
Uma Borate, MD, MBBS

# Conference Agenda (continued)

8:30 a.m. Cellular Therapy in AML and MDS: Are We Lagging Behind or Making Progress?  
Naval G. Daver, MD

8:45 a.m. Questions and Answers

9:00 a.m. How I Treat MDS in 2025  
Guillermo Garcia-Manero, MD

9:15 a.m. Treatment of Lower Risk MDS: Erythropoiesis-Stimulating Agents (ESA) and Beyond  
Jacqueline S. Garcia, MD

9:30 a.m. Moving Beyond Hypomethylating Agent in Higher Risk MDS: Lessons Learned From Prior Failures  
Amer M. Zeidan, MBBS, MHS

9:45 a.m. Triplet Therapies in MDS  
Mikkael A. Sekeres, MD, MS

10:00 a.m. Managing Chronic Myelomonocytic Leukemia (CMML)  
Guillermo Montalbán Bravo, MD

10:15 a.m. Questions and Answers

10:30 a.m. Break

## To Transplant or Not to Transplant?

Moderators: Krishna Gundabolu, MBBS, MS and Mary M. Horowitz, MD, MS

10:50 a.m. Transplanting Lower Risk MDS: Are There Any Patients Who Would Benefit?  
Marcos J. de Lima, MD

11:05 a.m. Transplanting Higher Risk MDS: Should Any Patients Not Be Transplanted?  
Mary M. Horowitz, MD, MS

11:20 a.m. Upfront vs. Delayed Transplant for AML in Era of Novel Treatments and Maintenance Therapy  
Upfront: Vijaya Raj Bhatt, MBBS, MS  
Delayed: Andrew Wei, MBBS, PhD

11:50 a.m. Questions and Answers

12:05 p.m. Lunch Break (On Your Own)

## Ask the Experts

### Allogeneic Stem Transplantation

Moderators: Partow Kebriaei, MD and Catherine E. Lai, MD, MPH

1:00 p.m. Supportive Care in Older Adults Undergoing Transplant  
Tanya M. Wildes, MD, MSCI

1:15 p.m. Acute Lymphoblastic Leukemia (ALL) Transplant: Upfront Indications and Consolidation Transplant Post-CAR T-Cell  
Partow Kebriaei, MD

1:30 p.m. Improving Outcomes of Patients with Myelofibrosis Who Need Transplant  
Nicolaus M. Kröger, MD

1:45 p.m. Preventing Post-Transplant Relapses  
Marcos J. de Lima, MD

2:00 p.m. Immune Reconstitution After Allogeneic Transplant  
Krishna Komanduri, MD

2:15 p.m. Prevention of Chronic Graft-Versus-Host Disease  
Shannon R. McCurdy, MD

2:30 p.m. Questions and Answers

2:45 p.m. Break

## Meet the Experts

3:00 p.m. Acute Lymphoblastic Leukemia (ALL)c  
Moderator: Marlise R. Luskin, MD, MSCE  
Experts: Stephan A. Grupp, MD, PhD; Lori Muffy, MD, MS; and Nitin Jain, MD

4:00 p.m. Myeloproliferative Neoplasms (MPN)  
Moderator: Naveen Pemmaraju, MD  
Experts: Ruben Mesa, MD, FACP; Jacqueline S. Garcia, MD; and Laura C. Michaelis, MD

5:00 p.m. Adjourn

## Conference Dinner

7:00-10:00 p.m.

Conference participants and registered accompanying guests are invited to join. Name badges required.

## Friday, July 18

7:00 a.m. Continental Breakfast

## Chronic Myelogenous Leukemia (CML)

Moderators: Jane F. Apperley, MBChB, MD, FRCP, FRCPath and Jorge E. Cortes, MD

7:45 a.m. Response Assessment in CML  
Jerald P. Radich, MD

8:00 a.m. Tyrosine Kinase Inhibitor (TKI) in Upfront Management of CML: Is One Superior to Others?  
Michael M. Haddadin, MBBS

8:15 a.m. Management of CML Not Meeting Milestones  
Fadi Haddad, MD

8:30 a.m.	3rd Generation ABL1 Kinase Inhibitors – When and How to Use Them Jorge E. Cortes, MD
8:45 a.m.	Questions and Answers
9:00 a.m.	Stopping Tyrosine Kinase Inhibitor in CML: When and How Jorge E. Cortes, MD
9:15 a.m.	Mitigating Toxicities Associated with TKI Jane F. Apperley, MBChB, MD, FRCP, FRCPath
9:30 a.m.	Questions and Answers
9:45 a.m.	Break

## Chronic Lymphocytic Leukemia (CLL)

Moderators: Matthew Lunning, DO, FACP and Julie M. Vose, MD, MBA

### Optimal Upfront Treatment in CLL: A Moving Target

10:05 a.m.	Younger Patients R. Gregory Bociek, MD, MSc, FRCP(C)
10:20 a.m.	Older Patients Nitin Jain, MD
10:35 a.m.	Questions and Answers

### Management of Relapsed CLL

10:50 a.m.	Moving CAR T-Cell Therapy to the Center: Lessons Learned in Lymphoma Matthew Lunning, DO, FACP
11:05 a.m.	Double Refractory CLL: An Emerging Clinical Challenge Susan M. O'Brien, MD
11:20 a.m.	Richter Transformation William G. Wierda, MD, PhD
11:35 a.m.	Questions and Answers
11:50 a.m.	Concluding Remarks Matthew Lunning, DO, FACP
12:00 p.m.	Adjourn

## Accreditation



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the

American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### PHYSICIANS

The University of Nebraska Medical Center designates this live activity for a maximum of 23.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NURSES

The University of Nebraska Medical Center designates this activity for up to 23.75 ANCC contact hours. Nurses should claim only the contact hours commensurate with the extent of their participation in the activity.

### PHARMACISTS


The University of Nebraska Medical Center designates this activity for 23.75 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity.

## Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 23.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
- 23.75 MOC points in the American Board of Pathology's (ABPATH) Maintenance of Certification (MOC) program.

It is the CME Provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.





# Conference Faculty

## **Jane F. Apperley, MBChB, MD, FRCP, FRCPath**

Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

## **Vijaya Raj Bhatt, MBBS, MS** ★

Professor; Medical Director, Leukemia Program, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## **Aleh (Oleg) Bobr, MD**

Assistant Professor; Medical Director, Blood Bank and Tissue Services; Medical Director, Quality, Compliance, and Process Improvement; Medical Director, Regional Pathology Services; Associate Director of Apheresis Service; Consultant, Coagulation Testing Services, Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE

## **R. Gregory Bociek, MD, MSc, FRCP(C)**

Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## **Uma Borate, MD, MBBS**

Associate Professor, Division of Hematology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH

## **Katherine L. Byar, MSN, ANP, BC, BMTCN**®

Nurse Practitioner, Nebraska Medicine, Omaha, NE

## **Ryan D. Cassaday, MD**

Associate Professor, Division of Hematology and Oncology, University of Washington School of Medicine; Associate Professor, Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA

## **Jorge E. Cortes, MD**

Director, Georgia Cancer Center; Professor, Department of Medicine; Cecil F. Whitaker Jr. GRA Eminent Scholar Chair in Cancer, Medical College of Georgia, Augusta University, Augusta, GA

## **Naval G. Daver, MD**

Professor and Director, Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Marcos J. de Lima, MD**

Professor, Division of Hematology; Director of the Blood and Bone Marrow Transplant and Cellular Therapy Program, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH

## **Jacqueline S. Garcia, MD**

Assistant Professor of Medicine, Harvard Medical School; Assistant Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

## **Guillermo Garcia-Manero, MD**

Professor; Chief, Section of Myelodysplastic Syndromes; Deputy Chair, Translational Research; Fellowship Program Director, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Allison M. Graner, PharmD, BCOP**

Oncology Pharmacist, Nebraska Medicine, Omaha, NE

## **Stephan A. Grupp, MD, PhD**

Yetta Deitch Novotny Endowed Chair in Pediatric Oncology; Section Chief of the Cellular Therapy and Transplant Section; Inaugural Director of the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy; Medical Director of the Cell and Gene Therapy Laboratory and Children's Hospital of Philadelphia, Philadelphia, PA

## **Krishna Gundabolu, MBBS, MS**

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## **Fadi Haddad, MD**

Assistant Professor, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Michael M. Haddadin, MBBS**

Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## **Mary M. Horowitz, MD, MS**

Robert A. Uihlein Jr. Professor of Hematologic Research; Director, Center for International Blood & Marrow Transplant Research; Associate Director, Cancer, Linda T. and John A. Mellows Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI

## **Elias Jabbour, MD**

Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Nitin Jain, MD** ★

Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Tapan M. Kadia, MD**

Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Hagop M. Kantarjian, MD**

Professor and Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Partow Kebriaei, MD**

Professor, Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Joseph D. Khoury, MD**

Stokes-Shackelford Professor and Chair, Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE

## **Heidi D. Klepin, MD, MS**

Professor, Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC

## **Krishna Komanduri, MD**

Julius R. Krevans, MD Distinguished Professorship in Internal Medicine; Professor and Chief, Division of Hematology and Oncology, Department of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, University of California San Francisco, San Francisco, CA

## **Marina Konopleva, MD, PhD** ★

Director, Leukemia Program; Co-Director, Blood Cancer Institute, Montefiore Einstein Comprehensive Cancer Center; Professor, Oncology and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY

## **Nicolaus M. Kröger, MD**

Professor of Medicine; Medical Director, Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany

## **Catherine E. Lai, MD, MPH**

Associate Professor of Clinical Medicine; Physician Leader, Leukemia Clinical Research Unit, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

## **Sanam Loghavi, MD**

Assistant Professor, Division of Pathology/Lab Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Kah Poh Loh, BMedSci, MBBCh, BAO, MS**

Assistant Professor, Division of Hematology and Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY

## **Matthew Lunning, DO, FACP** ★

Assistant Vice Chancellor of Clinical Research; Associate Vice Chair of Research; Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE



**Marlise R. Luskin, MD, MSCE**

Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

**Jared E. Matya, PharmD, BCOP**

Clinical Pharmacist Practitioner, Blood and Marrow Transplant/Cellular Therapy, Nebraska Medicine, Omaha, NE

**Shannon R. McCurdy, MD**

Assistant Professor of Medicine, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

**Ruben Mesa, MD, FACP**

President and Executive Director, Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center; Vice Dean for Cancer Programs and Professor of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC

**Laura C. Michaelis, MD**

Professor of Medicine, Division of Hematology-Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

**Kimberly Miller, BSN, RN, BMTCN®**

Manager Blood and Marrow Transplantation and CAR T Program, Nebraska Medicine, Omaha, NE

**Guillermo Montalbán Bravo, MD**

Assistant Professor, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Lori Muffly, MD, MS**

Associate Professor of Medicine, Blood and Marrow Transplantation & Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA

**Charles G. Mullighan, MBBS (Hons), MSc, MD**

Member, St. Jude Faculty; Deputy Director, Comprehensive Cancer Center; Co-Leader, Hematological Malignancies Program; Medical Director, St. Jude Biorepository; William E. Evans Endowed Chair, Department of Pathology, St. Jude Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital Comprehensive Cancer Center, Memphis, TN

**Susan M. O'Brien, MD**

Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue & Ralph Stern Center for Clinical Trials & Research; Professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Irvine, CA

**Olatoyosi Odenike, MD**

Professor of Medicine; Director, Leukemia Program; Division of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL

**Elli Papaemmanuil, PhD**

Associate Attending, Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

**Mrinal S. Patnaik, MBBS**

Physician Scientist, Division of Hematology, Department of Internal Medicine; Chair, Acute Leukemia and Myeloid Neoplasms Group; Scientific Director, Epigenetics Developmental Laboratory and the Epigenomics Program, Mayo Clinic, Rochester, MN

**Shilpa Paul, PharmD, BCOP**

Clinical Pharmacy Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX

**Naveen Pemmaraju, MD**

Professor, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Keith W. Pratz, MD**

Associate Professor of Medicine; Section Chief, Leukemia; Director, Leukemia Program, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

**Jerald P. Radich, MD**

Professor, Translational Science & Therapeutics Division; Kurt Enslin Endowed Chair; Professor, Division of Hematology and Oncology, Fred Hutch Cancer Center, University of Washington School of Medicine, Seattle, WA

**Caitlin R. Rausch, PharmD, BCOP**

Clinical Pharmacy Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX

**Rachael L. Schmidt, DNP, FNP-C, AOCNP®**

Program Director, Survivorship and Cancer Risk and Prevention; Assistant Director, Health Promotion and Screening, Office of Community Outreach and Engagement Health Promotion Unit, The Fred & Pamela Buffett Cancer Center, Nebraska Medicine, Omaha, NE

**Kim Schmit-Pokorny, MSN, RN, OCN®, BMTCN®**

Director BMT, CAR T, Cellular Therapy and Gene Therapy Program, Nebraska Medicine, Omaha, NE

**Mikael A. Sekeres, MD, MS**

Professor of Medicine and Chief, Division of Hematology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami Health System, Miami, FL

**Wendy Stock, MD**

Anjali Seth Nayak Professor of Medicine, Division of Biological Sciences, Department of Medicine, University of Chicago, Chicago, IL

**Richard M. Stone, MD**

Director of the Adult Acute Leukemia Program, Dana-Farber Cancer Institute, Boston, MA

**Joann B. Sweasy, PhD**

Director, Fred & Pamela Buffett Cancer Center; Director, Eppley Institute for Research in Cancer and Allied Diseases; Professor, Eppley Institute, University of Nebraska Medical Center, Omaha, NE

**Geoffrey L. Uy, MD**

Professor, Division of Oncology, John T. Milliken Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO

**Julie M. Vose, MD, MBA**

Division Chief and George and Peggy Payne Distinguished Chair of Oncology, Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**Euinice S. Wang, MD**

Chief of the Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY

**Andrew Wei, MBBS, PhD**

Professor; Adjunct Professor (Research), Australian Centre for Blood Diseases, Monash University, Victoria, Australia

**William G. Wierda, MD, PhD**

Professor of Medicine; Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey; Section Chief, Chronic Lymphocytic Leukemia; Center Medical Director; Executive Medical Director, Inpatient Medical Services; Deputy Department Chair, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Tanya M. Wildes, MD, MSCI**

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**Amer M. Zeidan, MBBS, MHS**

Associate Professor, Section of Hematology, Department of Internal Medicine, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT

**★ Conference Director**